Cross-reactive neutralizing antibody against pandemic 2009 H1N1 influenza a virus in intravenous immunoglobulin preparations

Pediatr Infect Dis J. 2011 Jan;30(1):67-9. doi: 10.1097/INF.0b013e3181f127be.

Abstract

Prepandemic intravenous immunoglobulin (IVIG) and sera from Kawasaki disease patients treated with this IVIG were analyzed for 2009 H1N1-specific microneutralization and hemagglutination inhibition antibodies. All 6 different IVIG preparations tested had significant levels of cross-reactive-specific antibody at a concentration of 2.0 g/dL of immunoglobulin. Sera from 18 of 19 Kawasaki disease patients had significant increases of cross-reactive-specific antibody after 2.0 g/kg of prepandemic IVIG. These results suggest a role for adjunctive IVIG therapy for severe and/or drug-resistant 2009 H1N1 virus and other highly antigenically drifted influenza strains, particularly in the immunocompromised.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Neutralizing / administration & dosage
  • Antibodies, Neutralizing / immunology*
  • Cell Line
  • Child
  • Child, Preschool
  • Cross Reactions / immunology
  • Dogs
  • Dose-Response Relationship, Immunologic
  • Hemagglutination Inhibition Tests
  • Humans
  • Immunoglobulins, Intravenous / administration & dosage
  • Immunoglobulins, Intravenous / immunology*
  • Infant
  • Influenza A Virus, H1N1 Subtype / immunology*
  • Influenza, Human / epidemiology
  • Influenza, Human / immunology
  • Influenza, Human / prevention & control
  • Influenza, Human / virology*
  • Mucocutaneous Lymph Node Syndrome / immunology
  • Neutralization Tests
  • Pandemics

Substances

  • Antibodies, Neutralizing
  • Immunoglobulins, Intravenous